Compare Sanofi SA (SNY) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Waste Management, Inc. — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Waste Management, Inc. trades at $226.84 (market cap $90.68B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | WM | |
|---|---|---|
Market Cap | $104.30B | $90.68B |
Sector | Health | Industrials |
52-Week High | $52.34 | $246.51 |
52-Week Low | $41.33 | $196.77 |
Enterprise Value | $124.19B | $113.47B |
Dividend Yield | 5.55% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
WM trades at $226.19, down 0.18% today, with a neutral technical signal and strong fundamentals. Recent Q2 2026 earnings beat estimates at $2.02 per share, driven by pricing discipline and margin gains. Revenue growth is steady, with 2025 revenue at $25.20 billion, though net income margin dipped to 10.74%. The stock shows a bullish analyst consensus with a $263.43 price target, supported by 20 buy ratings and no sell recommendations. Institutional activity includes mixed trades, such as Bank of America reducing holdings by 6.1% in Q1 2026 (SEC filing, 2026-08-01).
Outlook remains positive due to consistent earnings beats and operational efficiency, but risks include high valuation ratios like a P/E of 59.74 and rising debt levels, with total liabilities at $36.31 billion in 2024. Investors should weigh growth potential against margin pressures and macroeconomic headwinds affecting waste volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
